JPRN-UMIN000039049已完成2 期
Phase II study of VAC2.2(vincristine, actinomycin-D, cyclophosphamide)/ VA(vincristine, actinomycin-D) therapy for patients with newly diagnosed low-risk subset B rhabdomyosarcoma. - Phase II study of VAC2.2/VA therapy for patients with newly diagnosed low-risk subset B rhabdomyosarcoma.
Japan Rhabdomyosarcoma Study Group0 个研究点目标入组 16 人开始时间: 2020年1月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 18years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) patients with synchronous or metachronous concomitant malignancies 2) patients with prior history of chemotherapy 3) patients with prior history of radiation therapy 4) Female patients who are pregnant or breastfeeding mother 5) patients with contraindication of drugs used in this study 6) patients with Charcot-Marie-Tooth disease, varicella or pentostatin medication 7) Patients with any other inappropriate condition judged by physician
研究者
相似试验
招募中
2 期
Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) followed by VA for patients with newly diagnosed low-risk subset A rhabdomyosarcomarhabdomyosarcomaJPRN-UMIN000020891Japan Rhabdomyosarcoma Study Group22
招募中
2 期
Phase II study of VAC1.2/VA therapy for patients with newly diagnosed low-risk subset A rhabdomyosarcoma.RhabdomyosarcomaJPRN-jRCTs051180206Tsuchiya Kunihiko22
已完成
2 期
Phase II study of VAC1.2(vincristine, actinomycin-D, cyclophosphamide) therapy for patients with newly diagnosed low-risk subset A rhabdomyosarcoma.rhabdomyosarcomaJPRN-UMIN000039048Japan Rhabdomyosarcoma Study Group12
招募中
不适用
Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed intermediate rhabdomyosarcoma.rhabdomyosarcomaJPRN-UMIN000023956Japan Rhabdomyosarcoma Study Group40
招募中
2 期
Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma.rhabdomyosarcomaJPRN-UMIN000017004Japan Rhabdomyosarcoma Study Group18